Moreover, the network pharmacology approach suggested that ERK, STAT3, PI3K, Akt, and mTOR signaling pathways might be involved in the anticancer activity of 6‐shogaol on NSCLC cells. Here, MTOR is linked to non-small cell lung carcinoma.